Cover Image
市場調查報告書

PharmaPoint:氣喘--全球醫藥品的預測與市場分析

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 319761
出版日期 內容資訊 英文 383 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:氣喘--全球醫藥品的預測與市場分析 PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 383 Pages
簡介

全球每年約有25萬人因為氣喘等──只要給予正確治療就能簡單痊癒的疾病──而亡。由於市場飽和化及治療法效能相對較低,氣喘治療藥市場在過去十年成長率一直停留在低水準。既有的治療藥也面臨與學名藥的競爭。但新上市的標的療法用生技藥品(共7種)、及一天只要服用一次的新一代吸入式藥劑的出現,預測市場今後將會大大成長。這將不只提高生技醫藥品市場成長率,更揭開了治療氣喘用個別化醫療等新時代之序幕。反映「氣喘的非對稱性相當高」這樣的認知,標的療法用平台產品(處於後期階段之物)的組合數愈來愈多。

本報告提供全球主要10個國家氣喘的治療方法相關最新研究·開發情形和市場未來展望分析,提供疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),已上市/臨床實驗中主要的治療藥簡介(功效·安全性·市場競爭力),全球整體·各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
    • 氣喘的家族病史,兒童·成人是氣喘的強力預測因素
    • 青春期,少年少女的氣喘風險變動
    • 懷孕中抽煙將大大增加兒童氣喘的風險
    • 過敏原是普遍認知的氣喘觸發器
    • 職場暴露佔成人氣喘患者發病原因11%是最大的因素
    • 不同(非人種)城市生活環境,氣喘的風險約增加50%
    • 肥胖症的情況,氣喘發病風險大體上約為3倍
    • 90%的氣喘患者容易引發胃食道逆流症(GERD)
    • 85%氣喘患者有過敏性鼻炎
    • 很多氣喘患者也容易併發恐慌症,重度的影響疾病管理
    • 39%的氣喘患者高可能性引發憂鬱症
  • 全球趨勢
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 澳洲
    • 中國
    • 印度
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 氣喘的流行病學預測(今後10年)
    • 氣喘的一生患病人數
    • 氣喘的各年齡一生患病人數
    • 氣喘的男女一生患病人數
    • 已調整年齡的氣喘一生患病人數
    • 氣喘的一生患病人數的分佈:嚴重度別
  • 議論
    • 流行病學趨勢相關結論
    • 分析的限制
    • 分析的優勢

第5章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療方法的指南,臨床診療及代表性的處方藥
    • 臨床診療
  • 美國
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國
  • 日本
  • 澳洲

第6章 競爭評估

  • 概要
  • 策略性競爭評估
  • 吸入皮質類固醇劑
    • Flovent (fluticasone propionate)
    • Pulmicort (budenoside)
    • Other Inhaled Corticosteroids
  • 持續性β促效劑
    • 概要
  • 吸入類固醇藥/持續性β促效劑
    • Advair (fluticasone propionate/salmeterol xinafoate)
    • Symbicort (budenoside/formoterol fumarate)
    • Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
    • Dulera (mometasone furoate/formoterol fumarate)
    • Flutiform (fluticasone propionate/formoterol fumarate)
    • Fostair (beclomethasone dipropionate/formoterol fumarate)
  • 白三烯拮抗劑
    • Singulair (montelukast)
    • Other Leukotriene Modifiers
  • 短時間作用型β促效劑
    • 概要
    • 有效性
    • 安全性
  • 標靶治療
    • Xolair(Omalizumab)
  • 抗膽鹼藥
    • supiriba(Tiotropium bromide)

第7章 未滿足需求及機會

  • 概要
  • 重病氣喘的管理的個體化治療
    • 未滿足需求
    • 差距分析
    • 機會
  • 改善病人依從性
  • 低成本的氣喘治療
  • 兒童氣喘的恰當診斷

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 各國臨床實驗趨勢
    • 臨床實驗的階段和情形
  • 有潛力的藥劑和臨床開發
    • Fluticasone furoate
    • Cinquil (reslizumab)
    • Bosatria (mepolizumab)
    • Lebrikizumab
    • Benralizumab
    • Dupilumab
    • Quilizumab
    • Tralokinumab

第9章 現在及未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • GlaxoSmithKline
    • Merck & Co.
    • AstraZeneca/MedImmune
    • Novartis
    • Roche/Genentech
    • Teva
    • Boehringer Ingelheim

第10章 市場預測

  • 全球市場
    • 預測
    • 推動·阻礙要素:全世界的問題
  • 美國
    • 預測
    • 主要的活動
    • 推動·阻礙要素
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲

第11章 附錄

圖表一覽

目錄
Product Code: GDHC83PIDR

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Highlights

Key Questions Answered

  • Asthma symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 5-10% of people with asthma, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market Will the drugs under development fulfil the unmet needs of the asthma market
  • The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. Will the late-stage drugs make a significant impact on the asthma market What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market
  • The prevalence of environmental diseases, including asthma, is increasing worldwide, with an estimated 400 million people likely to suffer from asthma in 2025. How will epidemiological changes impact the growth of the future market

Key Findings

  • The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
  • The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
  • Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.
  • The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.

Scope

  • Overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global asthma therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. A family history of asthma is a strong predictor for asthma in children and adults
    • 4.2.2. Puberty alters the risk for asthma in boys and girls
    • 4.2.3. Maternal smoking during pregnancy greatly increases the risk of childhood asthma
    • 4.2.4. Allergens are well-known asthma triggers
    • 4.2.5. Common workplace exposures account for up to 11% of asthma cases in adults
    • 4.2.6. Urban living conditions, not race, increase the risk of asthma by almost 50%
    • 4.2.7. Obesity almost triples the risk of developing asthma
    • 4.2.8. Asthmatics are 90% more likely to develop GERD
    • 4.2.9. 85% of asthmatics have allergic rhinitis
    • 4.2.10. Panic disorders are common in asthmatics and severely impact disease control
    • 4.2.11. 39% of asthmatics are likely to develop depression
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. France
    • 4.3.3. Germany
    • 4.3.4. Italy
    • 4.3.5. Spain
    • 4.3.6. UK
    • 4.3.7. Japan
    • 4.3.8. Australia
    • 4.3.9. China
    • 4.3.10. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiology Forecast for Asthma (2013-2023)
    • 4.5.1. Lifetime Prevalent Cases of Asthma
    • 4.5.2. Age-Specific Lifetime Prevalent Cases of Asthma
    • 4.5.3. Sex-Specific Lifetime Prevalent Cases of Asthma
    • 4.5.4. Age-Standardized Lifetime Prevalence of Asthma
    • 4.5.5. Distribution of Lifetime Prevalent Cases of Asthma by Severity
  • 4.6. Discussion
    • 4.6.1. Conclusions on Epidemiology Trends
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Spain
  • 5.6. Italy
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Australia

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Inhaled Corticosteroids
    • 6.3.1. Flovent (fluticasone propionate)
    • 6.3.2. Pulmicort (budenoside)
    • 6.3.3. Other Inhaled Corticosteroids
  • 6.4. Long-Acting Beta-Agonists
    • 6.4.1. Overview
  • 6.5. Inhaled Corticosteroids/Long-Acting Beta-Agonists
    • 6.5.1. Advair (fluticasone propionate/salmeterol xinafoate)
    • 6.5.2. Symbicort (budenoside/formoterol fumarate)
    • 6.5.3. Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
    • 6.5.4. Dulera (mometasone furoate/formoterol fumarate)
    • 6.5.5. Flutiform (fluticasone propionate/formoterol fumarate)
    • 6.5.6. Fostair (beclomethasone dipropionate/formoterol fumarate)
  • 6.6. Leukotriene Modifiers
    • 6.6.1. Singulair (montelukast)
    • 6.6.2. Other Leukotriene Modifiers
  • 6.7. Short-Acting Beta-Agonists
    • 6.7.1. Overview
    • 6.7.2. Efficacy
    • 6.7.3. Safety
  • 6.8. Targeted Therapies
    • 6.8.1. Xolair (omalizumab)
  • 6.9. Anticholinergics
    • 6.9.1. Spiriva (tiotropium bromide)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Personalized Therapies to Control Severe Asthma
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Better Patient Compliance
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Lower Cost of Asthma Medications
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Proper Diagnosis of Asthma in Children
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
    • 8.2.2. Clinical Trials by Phase and Trial Status
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Fluticasone furoate
    • 8.3.2. Cinquil (reslizumab)
    • 8.3.3. Bosatria (mepolizumab)
    • 8.3.4. Lebrikizumab
    • 8.3.5. Benralizumab
    • 8.3.6. Dupilumab
    • 8.3.7. Quilizumab
    • 8.3.8. Tralokinumab

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. GlaxoSmithKline
    • 9.3.2. Merck & Co.
    • 9.3.3. AstraZeneca/MedImmune
    • 9.3.4. Novartis
    • 9.3.5. Roche/Genentech
    • 9.3.6. Teva
    • 9.3.7. Boehringer Ingelheim

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Australia
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Asthma Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Key Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. About the Authors
    • 11.6.1. Author
    • 11.6.2. Author/Reviewer
    • 11.6.3. Reviewer
    • 11.6.4. Epidemiologist
    • 11.6.5. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: GINA Guidelines for Classification of Asthma by Severity
  • Table 3: Risk Factors and Comorbidities of Asthma
  • Table 4: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011
  • Table 5: Trends in the Prevalence (%) of Self-Reported Asthma in Children in Spain
  • Table 6: Trends in the Lifetime Prevalence (%) of Asthma in the UK
  • Table 7: Lifetime Prevalence (%) of Asthma in Children in China
  • Table 8: Prevalence (%) of Asthma in Children and Adults in India
  • Table 9: Questions Asked to Assess Lifetime Asthma Prevalence
  • Table 10: 10MM, Epidemiological Sources of Lifetime Asthma Prevalence Data
  • Table 11: 10MM, Epidemiological Sources of Asthma Severity Data
  • Table 12: Overview of the Ellis Criteria for Childhood Asthma Severity Classification
  • Table 13: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023
  • Table 14: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), (Row %), 2013
  • Table 15: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, All Ages, N (Row %), 2013
  • Table 16: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Row %), 2013
  • Table 17: Treatment Guidelines for Asthma by Country
  • Table 18: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 19: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 20: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 21: Country Profile, Asthma Management - US
  • Table 22: Country Profile - Asthma Management, France
  • Table 23: Country Profile, Asthma Management - Germany
  • Table 24: Country Profile, Asthma Management - Spain
  • Table 25: Country Profile, Asthma Management - Italy
  • Table 26: Country Profile, Asthma Management - UK
  • Table 27: Country Profile, Asthma Management - Japan
  • Table 28: Country Profile, Asthma Management - Australia
  • Table 29: Leading Treatments for Asthma, 2014
  • Table 30: Product Profile - Flovent
  • Table 31: Efficacy - Flovent Diskus Versus Placebo
  • Table 32: Adverse Events Related to Flovent Diskus
  • Table 33: Flovent SWOT Analysis, 2014
  • Table 34: Global Sales Forecast ($) for Flovent, 2013-2023
  • Table 35: Product Profile - Pulmicort
  • Table 36: Pulmicort-Associated Adverse Events
  • Table 37: Pulmicort SWOT Analysis, 2014
  • Table 38: Global Sales Forecast ($) for Pulmicort, 2013-2023
  • Table 39: Summary of Other Marketed ICSs for Asthma Treatment, 2014
  • Table 40: Product Profile - Advair
  • Table 41: Efficacy - Advair Diskus Versus Its Individual Components
  • Table 42: Advair, Frequency of Drug-Related Adverse Events
  • Table 43: Advair SWOT Analysis, 2014
  • Table 44: Global Sales Forecast ($) for Advair, 2013-2023
  • Table 45: Product Profile - Symbicort
  • Table 46: Efficacy - Symbicort Versus Its Individual Components
  • Table 47: Symbicort, Frequency of Drug-Related Adverse Events
  • Table 48: Symbicort SWOT Analysis, 2014
  • Table 49: Global Sales Forecast ($) for Symbicort, 2013-2023
  • Table 50: Product Profile - Breo Ellipta
  • Table 51: Efficacy - Breo Ellipta Versus Flovent
  • Table 52: Safety - Breo Ellipta Versus Flovent
  • Table 53: Breo Ellipta SWOT Analysis, 2014
  • Table 54: Global Sales Forecast ($) for Breo Ellipta, 2013-2023
  • Table 55: Product Profile - Dulera
  • Table 56: Efficacy - Dulera Versus Its Individual Components
  • Table 57: Dulera - Frequency of Drug-Related Adverse Events
  • Table 58: Dulera SWOT Analysis, 2014
  • Table 59: Global Sales Forecast ($) for Dulera, 2013-2023
  • Table 60: Product Profile - Flutiform
  • Table 61: Efficacy - Flutiform Versus Advair
  • Table 62: Safety - Flutiform Versus Advair
  • Table 63: Flutiform SWOT Analysis, 2014
  • Table 64: Global Sales Forecast ($) for Flutiform, 2013-2023
  • Table 65: Product Profile - Fostair
  • Table 66: Efficacy - Fostair Versus Symbicort
  • Table 67: Safety - Fostair Versus Symbicort
  • Table 68: Fostair SWOT Analysis, 2014
  • Table 69: Global Sales Forecast ($) for Fostair, 2013-2023
  • Table 70: Product Profile - Singulair
  • Table 71: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort
  • Table 72: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort
  • Table 73: Singulair SWOT Analysis, 2014
  • Table 74: Global Sales Forecast ($) for Singulair, 2013-2023
  • Table 75: Overview of the Leading SABAs for Asthma Treatment, 2014
  • Table 76: Efficacy - Nebulized Levalbuterol Versus Nebulized Albuterol
  • Table 77: Adverse Events Related to Nebulized Levalbuterol and Nebulized Albuterol
  • Table 78: Product Profile - Xolair
  • Table 79: Efficacy - Xolair Versus Placebo
  • Table 80: Xolair SWOT Analysis, 2014
  • Table 81: Global Sales Forecast ($) for Xolair, 2013-2023
  • Table 82: Product Profile - Spiriva
  • Table 83: Efficacy - Spiriva's Versus LABA and Double-Dose ICS
  • Table 84: Adverse Events Related to the Use of Spiriva
  • Table 85: Spiriva SWOT Analysis, 2014
  • Table 86: Global Sales Forecast ($) for Spiriva, 2013-2023
  • Table 87: Unmet Need and Opportunity in Asthma
  • Table 88: Asthma - Clinical Trials by Phase and Status, 2014
  • Table 89: Asthma - Late Stage Pipeline, 2014
  • Table 90: Product Profile - Fluticasone Furoate
  • Table 91: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate
  • Table 92: Fluticasone Furoate Safety Profile
  • Table 93: Fluticasone Furoate SWOT Analysis, 2014
  • Table 94: Global Sales Forecast ($) for Fluticasone Furoate, 2013-2023
  • Table 95: Product Profile - Cinquil
  • Table 96: Efficacy of Cinquil Versus Placebo
  • Table 97: Cinquil's Safety Profile
  • Table 98: Cinquil SWOT Analysis, 2014
  • Table 99: Global Sales Forecast ($) for Cinquil, 2013-2023
  • Table 100: Product Profile - Bosatria
  • Table 101: Efficacy of Bosatria Versus Placebo
  • Table 102: Bosatria's Safety Profile
  • Table 103: Bosatria SWOT Analysis, 2012
  • Table 104: Global Sales Forecast ($) for Bosatria, 2013-2023
  • Table 105: Product Profile - Lebrikizumab
  • Table 106: Efficacy of Lebrikizumab Versus Placebo
  • Table 107: Lebrikizumab Safety Profile
  • Table 108: Lebrikizumab SWOT Analysis, 2014
  • Table 109: Global Sales Forecast ($) for Lebrikizumab, 2013-2023
  • Table 110: Product Profile - Benralizumab
  • Table 111: Efficacy of Benralizumab Versus Placebo
  • Table 112: Benralizumab SWOT Analysis, 2014
  • Table 113: Global Sales Forecast ($) for Benralizumab, 2013-2023
  • Table 114: Product Profile - Dupilumab
  • Table 115: Efficacy of Dupilumab Versus Placebo
  • Table 116: Dupilumab's Safety Profile
  • Table 117: Dupilumab SWOT Analysis, 2014
  • Table 118: Global Sales Forecast ($) for Dupilumab, 2013-2023
  • Table 119: Product Profile - Quilizumab
  • Table 120: Efficacy of Quilizumab Versus Placebo
  • Table 121: Quilizumab SWOT Analysis, 2014
  • Table 122: Global Sales Forecasts ($) for Quilizumab, 2013-2023
  • Table 123: Product Profile - Tralokinumab
  • Table 124: Efficacy of Tralokinumab Versus Placebo
  • Table 125: Tralokinumab's Safety Profile
  • Table 126: Tralokinumab SWOT Analysis, 2014
  • Table 127: Global Sales Forecast ($) for Tralokinumab, 2013-2023
  • Table 128: Key Companies in the Asthma Market, 2014
  • Table 129: GSK's Asthma Portfolio Assessment, 2014
  • Table 130: GSK SWOT Analysis, 2013
  • Table 131: Merck's Asthma Portfolio Assessment, 2014
  • Table 132: Merck SWOT Analysis, 2012
  • Table 133: AstraZeneca's Portfolio Assessment, 2014
  • Table 134: AstraZeneca SWOT Analysis, 2014
  • Table 135: Novartis' Asthma Portfolio Assessment, 2014
  • Table 136: Novartis SWOT Analysis, 2012
  • Table 137: Roche/Genentech's Portfolio Assessment, 2014
  • Table 138: Roche/Genentech SWOT Analysis, 2014
  • Table 139: Teva's Portfolio Assessment, 2014
  • Table 140: Teva SWOT Analysis, 2014
  • Table 141: Boehringer Ingelheim's Portfolio Assessment, 2014
  • Table 142: Boehringer Ingelheim SWOT Analysis, 2014
  • Table 143: Global Sales Forecast ($m) for Asthma, 2013-2023
  • Table 144: Global Asthma Market - Drivers and Barriers, 2014
  • Table 145: Sales Forecast ($m) for Asthma in the US 2013-2023
  • Table 146: Key Events Impacting Sales for Asthma in the US, 2013-2023
  • Table 147: Asthma Market - Drivers and Barriers in the US, 2013-2023
  • Table 148: Sales Forecast ($m) for Asthma in France, 2013-2023
  • Table 149: Key Events Impacting Sales for Asthma in France, 2013-2023
  • Table 150: French Asthma Market - Drivers and Barriers, 2013-2023
  • Table 151: Sales Forecast ($m) for Asthma in Germany, 2013-2023
  • Table 152: Key Events Impacting Sales for Asthma in Germany, 2013-2023
  • Table 153: Asthma Market - Drivers and Barriers in Germany, 2013-2023
  • Table 154: Sales Forecasts ($m) for Asthma in Italy, 2013-2023
  • Table 155: Key Events Impacting Sales for Asthma in Italy, 2013-2023
  • Table 156: Asthma Market - Drivers and Barriers in Italy, 2013-2023
  • Table 157: Sales Forecast ($m) for Asthma in Spain, 2013-2023
  • Table 158: Key Events Impacting Sales for Asthma in Spain, 2013-2023
  • Table 159: Asthma Market - Drivers and Barriers in Spain, 2013-2023
  • Table 160: Sales Forecast ($m) for Asthma in the UK, 2013-2023
  • Table 161: Key Events Impacting Sales for Asthma in the UK, 2013-2023
  • Table 162: Asthma Market - Drivers and Barriers in the UK, 2013-2023
  • Table 163: Sales Forecast ($m) for Asthma in Japan, 2013-2023
  • Table 164: Key Events Impacting Sales for Asthma in Japan, 2013-2023
  • Table 165: Asthma Market - Drivers and Barriers in Japan, 2013-2023
  • Table 166: Sales Forecast ($m) for Asthma in Australia, 2013-2023
  • Table 167: Key Events Impacting Sales for Asthma in Australia, 2013-2023
  • Table 168: Asthma Market - Drivers and Barriers in Australia, 2013-2023
  • Table 169: Key Launch Dates
  • Table 170: Key Patent Expiries
  • Table 171: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011
  • Figure 2: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023
  • Figure 3: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), 2013
  • Figure 4: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, N (Millions), 2013
  • Figure 5: 10MM, Age-Standardized Lifetime Prevalence of Asthma, All Ages, Men and Women, %, 2013
  • Figure 6: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Millions), 2013
  • Figure 7:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 8: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 9: Asthma Therapeutics - Clinical Trials by Country, 2014
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
  • Figure 11: Company Portfolio Gap Analysis in Asthma, 2013-2023
  • Figure 12: Global Sales for Asthma by Region, 2013-2023
  • Figure 13: Sales for Asthma in the US by Drug Class, 2013-2023
  • Figure 14: Sales for Asthma in France by Drug Class, 2013-2023
  • Figure 15: Sales for Asthma in Germany by Drug Class, 2013-2023
  • Figure 16: Sales for Asthma in Italy by Drug Class, 2013-2023
  • Figure 17: Sales for Asthma in Spain by Drug Class, 2013-2023
  • Figure 18: Sales for Asthma in the United Kingdom by Drug Class, 2013-2023
  • Figure 19: Sales for Asthma in Japan by Drug Class, 2013-2023
  • Figure 20: Sales for Asthma in Australia by Drug Class, 2013-2023
Back to Top